Cohance Lifesciences · NSE: COHANCE · BSE: 543064
Q4 FY23 results · Jan–Mar 2023
Cohance Lifesciences reported revenue from operations of ₹369.36 crore (up 1.5% from Q4 FY22) and net profit of ₹123.97 crore (up 35.2% from Q4 FY22) for Q4 FY23 (Jan–Mar 2023), on a consolidated basis.
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 369.36 | 363.85 | +1.5% | 353.77 | +4.4% |
| Other income | 11.40 | 16.87 | −32.4% | 13.01 | −12.4% |
| Total income | 380.76 | 380.72 | +0.0% | 366.78 | +3.8% |
| Profit before tax | 166.21 | 161.28 | +3.1% | 146.08 | +13.8% |
| Net profit for the period | 123.97 | 91.67 | +35.2% | 107.72 | +15.1% |
| EPS, basic (₹) | 4.87 | 3.60 | +35.3% | 4.23 | +15.1% |
| Net margin (%) | 33.6 | 25.2 | 30.4 |
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 364.39 | 363.85 | +0.1% | 348.49 | +4.6% |
| Other income | 10.75 | 134.40 | −92.0% | 12.51 | −14.0% |
| Total income | 375.14 | 498.24 | −24.7% | 361.00 | +3.9% |
| Profit before tax | 172.47 | 279.36 | −38.3% | 147.28 | +17.1% |
| Net profit for the period | 130.16 | 224.46 | −42.0% | 109.47 | +18.9% |
| EPS, basic (₹) | 5.11 | 8.82 | −42.1% | 4.30 | +18.8% |
| Net margin (%) | 35.7 | 61.7 | 31.4 |
Consolidated
- Filed with BSE
- 26 May 2023, 10:22 IST
- Board meeting
- 25 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 26 May 2023, 10:22 IST
- Board meeting
- 25 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE